Peptide inhibitors of hausp deubiquitinase
OwnerJae Junginventor
Life of this patent
Estimating the term…
Abstract
Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating ALL.
Claims18
A method for treating acute lymphoblastic leukemia (ALL) in a subject in need thereof, comprising administering to the subject an effective amount of a vIRF4 peptide fragment comprising an amino acid sequence of the group:
- vIRF4 aa 153-256;
- vIRF4 aa 608-758;
- vIRF4 aa 202-208;
- vIRF4 aa 211-216;
- vIRF4 aa 202-216 (vif1);
- vIRF4 aa 209-216;
- vIRF4 aa 153-216;
- vIRF4 aa 217-236;
- or vIRF4 aa 220-236 (vif2), or a biological equivalent of each thereof.
-11. (canceled)
A method for treating acute lymphoblastic leukemia (ALL) in a subject in need thereof, comprising administering to the subject an effective amount of a vIRF4 peptide fragment comprising an amino acid sequence of the group:
- vIRF4 aa 153-256 (SEQ ID NO:
- 11);
- vIRF4 aa 608-758 (SEQ ID NO:
- 12);
- vIRF4 aa 202-208 (SEQ ID NO:
- 13);
- vIRF4 aa 211-216(SEQ ID NO:
- 14);
- vIRF4 aa 202-216 (vif1) (SEQ ID NO:
- 1);
- vIRF4 aa 209-216 (SEQ ID NO:
- 6);
- vIRF4 aa 153-216 (SEQ ID NO:
- 15);
- vIRF4 aa 217-236 (SEQ ID NO:
- 16);
- or vIRF4 aa 220-236 (vif2) (SEQ ID NO:
- 2), or a biological equivalent of each thereof.
A method for treating acute lymphoblastic leukemia (ALL) in a subject in need thereof, comprising administering to the subject an effective amount of a vIRF4 peptide fragment consisting of an amino acid sequence selected from the group consisting of:
- vIRF4 aa 153-256 (SEQ ID NO:
- 11);
- vIRF4 aa 608-758 (SEQ ID NO:
- 12);
- vIRF4 aa 202-208 (SEQ ID NO:
- 13);
- vIRF4 aa 211-216 (SEQ ID NO:
- 14);
- vIRF4 aa 202-216 (vif1) (SEQ ID NO:
- 1);
- vIRF4 aa 209-216 (SEQ ID NO:
- 6);
- vIRF4 aa 153-216 (SEQ ID NO:
- 15);
- vIRF4 aa 217-236 (SEQ ID NO:
- 16);
- and vIRF4 aa 220-236 (vif2) (SEQ ID NO:
- 2), and a biological equivalent of each thereof.
A method for treating acute lymphoblastic leukemia (ALL) in a subject in need thereof, comprising administering to the subject an effective amount of a vIRF4 peptide fragment consisting of:
- (a) a cell penetrating domain, and
- (b) an amino acid sequence selected from the group consisting of:
- vIRF4 aa 153-256 (SEQ ID NO:
- 11);
- vIRF4 aa 608-758 (SEQ ID NO:
- 12);
- vIRF4 aa 202-208 (SEQ ID NO:
- 13);
- vIRF4 aa 211-216 (SEQ ID NO:
- 14);
- vIRF4 aa 202-216 (vif1) (SEQ ID NO:
- 1);
- vIRF4 aa 209-216 (SEQ ID NO:
- 6);
- vIRF4 aa 153-216 (SEQ ID NO:
- 15);
- vIRF4 aa 217-236 (SEQ ID NO:
- 16);
- and vIRF4 aa 220-236 (vif2) (SEQ ID NO:
- 2), and a biological equivalent of each thereof.
Dependencies are inferred from the claim text.